Both drugs are being developed by Novo Nordisk, likely reflecting a portfolio strategy: CagriSema as the first-to-market injectable combination, and amycretin as a follow-on oral option for patients who prefer pills
Ozempics creator, Novo Nordisk, is facing a class action suit in the Canadian court system, following the formation of a US class action centralized in Delaware
Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Avoid highly processed, high-fat meals, and drinks such as alcohol and soda that can make side effects worse
Active repletion through supplementation or injections is needed
If youre using a GLP-1 as part of your plan, you can get support with side effects and tips on how to develop sustainable habits with our GLP-1 Companion Program